| pubmed-article:8481509 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8481509 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8481509 | lifeskim:mentions | umls-concept:C0035569 | lld:lifeskim |
| pubmed-article:8481509 | lifeskim:mentions | umls-concept:C0194037 | lld:lifeskim |
| pubmed-article:8481509 | lifeskim:mentions | umls-concept:C0079731 | lld:lifeskim |
| pubmed-article:8481509 | lifeskim:mentions | umls-concept:C0796507 | lld:lifeskim |
| pubmed-article:8481509 | lifeskim:mentions | umls-concept:C1522673 | lld:lifeskim |
| pubmed-article:8481509 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:8481509 | pubmed:dateCreated | 1993-6-1 | lld:pubmed |
| pubmed-article:8481509 | pubmed:abstractText | Anti-B-blocked ricin (anti-B4-bR) combines the specificity of the anti-B4 (CD19) monoclonal antibody with the protein toxin "blocked ricin." In blocked ricin, affinity ligands are attached to the ricin B-chain to attenuate its lectin binding capacity. In a phase I trial, Anti-B4-bR was administered by 7-day continuous infusion to 12 patients in complete remission after autologous bone marrow transplantation (ABMT) for relapsed B-cell non-Hodgkin's lymphoma (NHL). Patients were treated at 20, 40, and 50 micrograms/kg/d for 7 days. Potentially therapeutic serum levels could be sustained for 3 to 4 days. The maximum tolerated dose was 40 micrograms/kg/d for 7 days (total 280 micrograms/kg). The dose-limiting toxicities were reversible grade IV thrombocytopenia and elevation of hepatic transaminases. Mild capillary leak syndrome was manifested by hypoalbuminemia, peripheral edema (4 patients), and dyspnea (1 patient). Anti-immunotoxin antibodies developed in 7 patients. Eleven patients remain in complete remission between 13 and 26 months post-ABMT (median 17 months). These results show that Anti-B4-bR can be administered with tolerable, reversible toxicities to patients with B-cell NHL in complete remission following ABMT. | lld:pubmed |
| pubmed-article:8481509 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8481509 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8481509 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8481509 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8481509 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8481509 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:8481509 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8481509 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8481509 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8481509 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8481509 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8481509 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8481509 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8481509 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8481509 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8481509 | pubmed:month | May | lld:pubmed |
| pubmed-article:8481509 | pubmed:issn | 0006-4971 | lld:pubmed |
| pubmed-article:8481509 | pubmed:author | pubmed-author:TaylorJ AJA | lld:pubmed |
| pubmed-article:8481509 | pubmed:author | pubmed-author:BlättlerW AWA | lld:pubmed |
| pubmed-article:8481509 | pubmed:author | pubmed-author:FreedmanA SAS | lld:pubmed |
| pubmed-article:8481509 | pubmed:author | pubmed-author:LambertJ MJM | lld:pubmed |
| pubmed-article:8481509 | pubmed:author | pubmed-author:KinsellaJJ | lld:pubmed |
| pubmed-article:8481509 | pubmed:author | pubmed-author:RabinoweS NSN | lld:pubmed |
| pubmed-article:8481509 | pubmed:author | pubmed-author:GribbenJ GJG | lld:pubmed |
| pubmed-article:8481509 | pubmed:author | pubmed-author:GrossbardM... | lld:pubmed |
| pubmed-article:8481509 | pubmed:author | pubmed-author:EliseoLL | lld:pubmed |
| pubmed-article:8481509 | pubmed:author | pubmed-author:EpsteinC LCL | lld:pubmed |
| pubmed-article:8481509 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8481509 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:8481509 | pubmed:volume | 81 | lld:pubmed |
| pubmed-article:8481509 | pubmed:geneSymbol | bcl-2 | lld:pubmed |
| pubmed-article:8481509 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8481509 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:8481509 | pubmed:pagination | 2263-71 | lld:pubmed |
| pubmed-article:8481509 | pubmed:dateRevised | 2009-11-19 | lld:pubmed |
| pubmed-article:8481509 | pubmed:meshHeading | pubmed-meshheading:8481509-... | lld:pubmed |
| pubmed-article:8481509 | pubmed:meshHeading | pubmed-meshheading:8481509-... | lld:pubmed |
| pubmed-article:8481509 | pubmed:meshHeading | pubmed-meshheading:8481509-... | lld:pubmed |
| pubmed-article:8481509 | pubmed:meshHeading | pubmed-meshheading:8481509-... | lld:pubmed |
| pubmed-article:8481509 | pubmed:meshHeading | pubmed-meshheading:8481509-... | lld:pubmed |
| pubmed-article:8481509 | pubmed:meshHeading | pubmed-meshheading:8481509-... | lld:pubmed |
| pubmed-article:8481509 | pubmed:meshHeading | pubmed-meshheading:8481509-... | lld:pubmed |
| pubmed-article:8481509 | pubmed:meshHeading | pubmed-meshheading:8481509-... | lld:pubmed |
| pubmed-article:8481509 | pubmed:meshHeading | pubmed-meshheading:8481509-... | lld:pubmed |
| pubmed-article:8481509 | pubmed:meshHeading | pubmed-meshheading:8481509-... | lld:pubmed |
| pubmed-article:8481509 | pubmed:meshHeading | pubmed-meshheading:8481509-... | lld:pubmed |
| pubmed-article:8481509 | pubmed:meshHeading | pubmed-meshheading:8481509-... | lld:pubmed |
| pubmed-article:8481509 | pubmed:meshHeading | pubmed-meshheading:8481509-... | lld:pubmed |
| pubmed-article:8481509 | pubmed:meshHeading | pubmed-meshheading:8481509-... | lld:pubmed |
| pubmed-article:8481509 | pubmed:meshHeading | pubmed-meshheading:8481509-... | lld:pubmed |
| pubmed-article:8481509 | pubmed:meshHeading | pubmed-meshheading:8481509-... | lld:pubmed |
| pubmed-article:8481509 | pubmed:meshHeading | pubmed-meshheading:8481509-... | lld:pubmed |
| pubmed-article:8481509 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8481509 | pubmed:articleTitle | Adjuvant immunotoxin therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. | lld:pubmed |
| pubmed-article:8481509 | pubmed:affiliation | Division of Tumor Immunology, Dana-Farber Cancer Institute, Boston, MA 02115. | lld:pubmed |
| pubmed-article:8481509 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8481509 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8481509 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:8481509 | pubmed:publicationType | Clinical Trial, Phase I | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8481509 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8481509 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8481509 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8481509 | lld:pubmed |
